IGHE and asthma: Furthermore, dupilumab ameliorated lung function by significantly increasing FEV1 and also improved the control of asthma symptoms, as well as decreasing the levels of relevant biomarkers of type 2 asthma such as FeNO and serum IgE concentrations [152].